Alzheimer’s drug saga prompts journal to scrutinize whistle-blowers

Publication requires complainants to disclose financial conflicts in the wake of controversy over Cassava Sciences’ experimental treatment simufilam.


https://www.nature.com/articles/d41586-023-00050-z?utm_source=Nature+Briefing&utm_campaign=9e3739a111-briefing-dy-20230116&utm_medium=email&utm_term=0_c9dfd39373-9e3739a111-43576073





Comments

Popular posts from this blog

Defamation lawsuits against Leonid Schneider (author of the "For Better Science" blog)

Comment moderation and freedom of speech at the social media site, PubPeer: challenges and issues